Korean journal of urology · 2010 · 21 citations · 21 references
MedicinePathologyUrologyGenitourinary OncologyProstate DiseaseUrologic OncologyCancer DiagnosisProstate BiopsyProstate CancerProstate PathologyProstatic PathologyUrologic Cancer DiagnosisBiopsy Of Prostate LesionsInitial BiopsyProstate Biopsy DiagnosisProstate Cancer DiagnosisProstate Needle Biopsy DiagnosisProstate Tumor MarkersProstate-specific Antigen VelocityUnivariate Analysis
PURPOSE: The factors that predict prostate cancer detection on repeat biopsy were evaluated in patients with atypical small acinar proliferation (ASAP) on the initial biopsy. MATERIALS AND METHODS: From 2003 to 2008, 3,130 men with suspected prostate cancer underwent a prostate needle biopsy, and 244 (7.8%) were diagnosed as having ASAP. One hundred seventy of 244 patients were rebiopsied at least once more. They were classified into a prostate cancer group and a noncancer group according to the final pathological diagnosis. The database of rebiopsied patients included age, initial prostate-specific antigen (PSA), PSA density (PSAD), PSA velocity (PSAV), total prostate volume (TPV), and transitional zone volume of the prostate (TZV). We compared differences in the aforementioned parameters between the 2 groups. RESULTS: A total of 57 patients (33.5%) with ASAP were ultimately shown to have prostate cancer. Univariate analysis showed that PSAD (p=0.002), PSAV (p=0.001), TPV (p=0.035), and TZV (p=0.005) differed significantly between the cancer and noncancer groups. The results of the multivariate analysis showed that PSAD (p=0.022), PSAV (p<0.001), and TPV (p=0.037) had a statistically significant correlation with cancer detection. CONCLUSIONS: PSAD, PSAV, and TPV are predictive factors of prostate cancer in patients with an initial diagnosis of ASAP of the prostate. Although repeat biopsy is mandatory irrespective of PSA values, the follow-up of PSA may help to estimate the probability of cancer in these men.
21
α-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer
Mark A. Rubin · JAMA · 2002 · 646 citations
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Patrick C. Walsh · PubMed · 2002 · 477 citations
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Jun Luo, Shan Zha, Jessica Hicks et al. · PubMed · 2002 · 297 citations
Follow-up of atypical prostate needle biopsies suspicious for cancer
Theresa Y. Chan, Jonathan I. Epstein · Urology · 1999 · 166 citations · Full text